Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
The primary objective of this study is to evaluate the safety and tolerability of oraldaily administration of TTI‐101 over a 12‐week treatment duration in participants withidiopathic pulmonary fibrosis (IPF).
Epistemonikos ID: ba057176fbc9043ed9433062fa0b7c4c6cbab755
First added on: Oct 02, 2023